Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer

Approximately 5-10% of patients with acute ischemic stroke (AIS) have known active cancer. These patients are at high risk for both recurrent AIS and major bleeding. The optimal antithrombotic strategy for cancer-related stroke is uncertain. This study compared clinical outcomes among patients with...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in neurology Jg. 16; S. 1530775
Hauptverfasser:	Kielkopf, Moritz C., Göcmen, Jayan, Venzin, Selina B., Steinauer, Fabienne, Branca, Mattia, Boronylo, Anna, Göldlin, Martina B., Kaesmacher, Johannes, Mujanovic, Adnan, Costamagna, Gianluca, Meinel, Thomas R., Seiffge, David J., Bücke, Philipp, Heldner, Mirjam R., Liberman, Ava L., Kamel, Hooman, Fischer, Urs, Arnold, Marcel, Pabst, Thomas, Berger, Martin D., Jung, Simon, Scutelnic, Adrian, Navi, Babak B., Beyeler, Morin
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland Frontiers Media S.A 2025
Schlagworte:	acute ischemic stroke antithrombotic drugs cancer embolic stroke of unknown source (ESUS) secondary prevention cancer secondary prevention antithrombotic drugs embolic stroke of unknown source (ESUS) acute ischemic stroke
ISSN:	1664-2295, 1664-2295
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!